Here are the 10-K annual reports from Greenland Mines Ltd. (GRML) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GRML and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRML filings page.
Greenland Mines Ltd (GRML) amended its annual report for the year ended December 31, 2025, revising product-candidate timelines, license disclosures, expense discussions, financial statements and disclosures on intangible assets and warrants in response to SEC staff comments. Its business includes gene-therapy candidates for neurodegenerative diseases, generic drugs and biosimilar biologics.
KLTO-202 and KLTO-101 are preclinical candidates. The company plans a first-in-human Phase I/II “Compassionate Use” study of KLTO-202 in late-stage ALS patients in 2027. KLTO-101 development is expected to follow KLTO-202 by six to nine months; if no corporate partner is found in 2026, the company plans to begin Phase I/II studies in 2027 after GMP manufacturing and IND-enabling studies. In March 2026, Greenland Mines Ltd completed its acquisition of Greenland Mines Corp., adding development and mining of critical and precious minerals to its operations.
Management reported that disclosure controls and internal control over financial reporting were ineffective as of December 31, 2025, citing inadequate accounting resources and lack of segregation of duties. Without additional funding, management said substantial doubt exists about the company’s ability to continue as a going concern for twelve months from the financial-statement date. It also said additional analyses supported the fair presentation of the 2025 financial statements.
Greenland Mines Ltd (GRML), formerly Klotho Neurosciences, described its medicine-development business and reported completing the acquisition of Greenland Mines Corp. in March 2026, adding critical- and precious-minerals development and mining.
Its medicine programs include licensed generic drugs and biosimilar biologics, plus a patented Klotho gene-therapy platform. Lead candidates KLTO-101 for Alzheimer’s disease and KLTO-202 for ALS are preclinical; Greenland Mines states it has not submitted an IND application for any gene therapy.
The company says additional funding from equity and/or debt securities is needed to execute development plans and continue operations. Without it, substantial doubt exists about its ability to continue as a going concern for twelve months from the financial statements’ date. Management found disclosure controls and internal controls over financial reporting ineffective as of December 31, 2025, citing inadequate accounting resources, lack of segregation of duties and a need for a stronger control environment. After additional analyses and procedures, management said the 2025 financial statements were fairly stated in all material respects under GAAP.